Timothy J. Murphy

Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity

John C. Byrd, Timothy J. Murphy, Robin Howard et al. · Journal of Clinical Oncology · 2001 · 511 citations

Pharmacy, Oncology, Pharmacokinetics +15

Rituximab Therapy in Hematologic Malignancy Patients With Circulating Blood Tumor Cells: Association With Increased Infusion-Related Side Effects and Rapid Blood Tumor Clearance

John C. Byrd, Jamie K. Waselenko, Thomas Maneatis et al. · Journal of Clinical Oncology · 1999 · 268 citations

Medicine, Hematology, Oncology +17

Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies

Ian W. Flinn, John C. Byrd, Candis Morrison et al. · Blood · 2000 · 214 citations

Medicine, Oncology, Pharmacotherapy +12

Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies

Ian W. Flinn, John C. Byrd, Candis Morrison et al. · Blood · 2000 · 191 citations

Medicine, Oncology, Pharmacotherapy +12

Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8–mediated apoptosis and down-regulation of c-FLIP protein

Jennifer L. Aron, Mark R. Parthun, Guido Marcucci et al. · Blood · 2003 · 173 citations

Life Sciences, Molecular Biology, Oncology +17